Jafron Biomedical Co Ltd
SZSE:300529
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
Accounts Receivables
Jafron Biomedical Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Accounts Receivables
¥72m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Accounts Receivables
¥41.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Accounts Receivables
¥1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
6%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Accounts Receivables
¥4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Accounts Receivables
¥2.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Accounts Receivables
¥3.3B
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jafron Biomedical Co Ltd
Glance View
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
See Also
What is Jafron Biomedical Co Ltd's Accounts Receivables?
Accounts Receivables
72m
CNY
Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Accounts Receivables amounts to 72m CNY.
What is Jafron Biomedical Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-16%
Over the last year, the Accounts Receivables growth was -49%. The average annual Accounts Receivables growth rates for Jafron Biomedical Co Ltd have been -36% over the past three years , -16% over the past five years .
You don't have any saved screeners yet
